Kết quả sớm điều trị của phác đồ TC trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV tại khoa Ung Bướu Bệnh viện Đại học Y Hải Phòng từ 1/2017 đến 1/2023=Early treatment results of tc regimen on patients with stage iiib-iv non-small cell lung cancer at the oncology department of Hai Phong Medical University Hospital from 1/2017 to 1/2023

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thúy Loan Cao, Lam Hòa Nguyễn, Hữu Thịnh Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.154-162

Bộ sưu tập: Metadata

ID: 245934

Thêm vào giỏ

Khoa Ung Bướu bệnh viện Đại học Y Hải Phòng được thành lập và điều trị 97 bệnh nhân UTPKTBN giai đoạn muộn từ tháng 1/2017 đến 1/2023 bằng phác đồ TC (Paclitaxel/Docetaxel + Carboplatin) có hiệu quả rõ rệt. * Kết quả: Tỉ lệ ĐƯ chung của phác đồ là 43,9%, ĐƯ hoàn toàn – 3,9%. ĐƯ cơ năng đạt 82,9% + Nhóm BN điều trị ≥ 6 đợt hóa chất ĐƯ cao hơn điều trị <
6
Với p <
0,001 + Nhóm BN nữ có tỉ lệ ĐƯ cao hơn nam
Với p <
0,05 Một số tác dụng phụ: - Trên hệ tạo huyết: Hầu hết ở độ I, II
1 trường hợp giảm tiểu cầu – 1,2%. - Ngoài hệ tạo huyết: Hầu hết ở độ I, Có 94,5% bệnh nhân bị rụng tóc. - Không có trường hợp nào phải dừng điều trị vì tác dụng phụ của thuốc. * Kết luận: Phác đồ TC là hiệu quả và là phác đồ đầu tay tại các cơ sở điều trị UTPKTBN giai đoạn tiến triển.The Oncology Department of Hai Phong Medical University Hospital was established and 97 patients treatment NSCLC late stage from January 2017 to January 2023 using the regimen TC (Paclitaxel/Docetaxel + Carboplatin) clearly effective. * Results: The overall response rate of the regimen is 43.9%, complete - 3.9%. Functional capacity reached 82.9% - The group of patients treated with ≥ 6 cycles of chemotherapy responded better than those treated with <
6 cycles
with p <
0.001 - The female patient group had a higher response rate than men, with p <
0.05 Side effects: - On the hematopoietic system: Mostly at levels I and II
1 case of thrombocytopenia – 1.2%. - Outside the hematopoietic system: Mostly at level I, 94.5% of patients have hair loss. - There was no case of stopping treatment because of drug side effects. * Conclusion: TC regimen is effective and is the first-line regimen at facilities treating advanced stage NSCLC.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR